Mineralys says Transform-HTN extension data on lorundrostat set for late-breaking AHA 2026 presentation
Bitget2026/09/23 20:06- Mineralys Therapeutics flagged new long-term efficacy and safety findings from its Transform-HTN open-label extension trial of lorundrostat.
- Results have not been presented yet; they are slated for a late-breaking session at American Heart Association Scientific Sessions 2026.
- The update supports the drug’s sustained blood-pressure control profile in uncontrolled hypertension, with safety remaining consistent over longer treatment.
- Presentation is scheduled for Nov. 8 in Chicago, positioning lorundrostat for higher visibility with clinicians and investors.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canton Network breaks 2 month range! – CC’s run to $0.15 depends on THIS zone
Analysis: Wall Street Is Not Yet Ready to Short AI in Large Numbers
Overseas capital is aggressively buying US stocks! Net inflows reached $942 billions over the past 12 months, marking a record since 1985.
According to data from the US Department of the Treasury, in the 12 months ending July this year, overseas investors made net purchases of US stocks totaling $942 billion, marking the highest rolling 12-month total since records began in 1985. The net purchases in the second quarter alone reached $426 billion, setting a new single-quarter record. Meanwhile, overseas demand for US Treasuries has noticeably cooled, with purchase volumes falling significantly. As a result, the US is facing higher costs in government debt financing.
Crypto prices
More
